JPMorgan Chase & Co. Boosts Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00

Solid Biosciences (NASDAQ:SLDB) had its price objective lifted by research analysts at JPMorgan Chase & Co. from $11.00 to $12.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 55.24% from the stock’s current price.

Several other research firms have also commented on SLDB. Wedbush reissued an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a research report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a research report on Friday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research note on Friday, March 20th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Solid Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $16.09.

Solid Biosciences Stock Up 6.9%

Shares of SLDB stock opened at $7.73 on Wednesday. The firm has a market cap of $602.24 million, a price-to-earnings ratio of -3.83 and a beta of 2.65. Solid Biosciences has a 52-week low of $2.41 and a 52-week high of $8.72. The company’s 50 day moving average is $6.57 and its 200 day moving average is $5.84.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. Analysts anticipate that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Insider Transactions at Solid Biosciences

In related news, COO David T. Howton sold 37,771 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $243,245.24. Following the completion of the transaction, the chief operating officer owned 116,753 shares in the company, valued at $751,889.32. This trade represents a 24.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kevin Tan sold 26,837 shares of Solid Biosciences stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $172,830.28. Following the sale, the chief financial officer directly owned 108,984 shares of the company’s stock, valued at approximately $701,856.96. This represents a 19.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 597,672 shares of company stock worth $3,816,546 over the last 90 days. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Solid Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of SLDB. Legal & General Group Plc boosted its position in Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after buying an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Solid Biosciences by 205.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after buying an additional 4,534 shares during the last quarter. Creative Planning purchased a new position in Solid Biosciences during the 2nd quarter worth approximately $57,000. Russell Investments Group Ltd. lifted its stake in Solid Biosciences by 142.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after acquiring an additional 5,991 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey lifted its stake in Solid Biosciences by 233.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after acquiring an additional 10,585 shares during the period. Institutional investors and hedge funds own 81.46% of the company’s stock.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Truist upgraded SLDB to “Strong‑Buy”, adding a near‑term positive catalyst that supports momentum and investor confidence. Zacks Article
• Positive Sentiment: JPMorgan raised its price target from $11 to $12 and maintained an “Overweight” rating — a ~55% upside vs. the current share level — which can attract institutional interest and buying. Benzinga Article
• Positive Sentiment: HC Wainwright raised multiple near‑term EPS estimates (Q1–Q4 2026) and materially improved its FY2026 outlook (from ~($2.12) to ($1.43)), while keeping a “Buy” rating and a $20 price target — signaling better expected near‑term performance and strong long‑term upside (FY2029–2030 turn to profitability). HC Wainwright Coverage
• Neutral Sentiment: Analyst optimism is concentrated in price targets and model revisions rather than new clinical readouts or revenue — the moves reflect expectations, not confirmed commercial progress; watch for upcoming company data or milestones to sustain gains. MarketBeat Summary
• Negative Sentiment: Consensus remains that Solid is not yet profitable (street FY current consensus still negative), so the stock is vulnerable to execution risk, trial setbacks, or any misses vs. these raised expectations. MarketBeat Financials

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.